Brought to you by 
Investors put $18.5mm into Intradigm through Series B
03 Oct 2008
Executive Summary
Intradigm (RNAi-based cancer therapeutics) raised $18.5mm through its Series B round. New investor Lilly Ventures (who also joins the company's board) led and was joined by other first-time buyers Roche Venture Fund and MP Healthcare Venture Management (a jointly owned investment venture of Mitsubishi Chemical and its Mitsubishi Tanabe Pharma division). Returning backers Frazier Healthcare Ventures, Alta Partners, MediBic Alliance Technology Fund, and Novartis Venture Fund also participated.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Investors put $18.5mm into Intradigm through Series B
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice